Adducts are described, obtainable from the reaction product of a secondary amine and a diketone, with carbon allotropes in which the carbon is sp.sup.2 hybridized, such as graphene, graphite, fullerene, carbon nanotubes and the like, and an inorganic oxide-hy-droxide. A process for preparing said adducts is also described.

Adducts are described, obtainable from the reaction product of a secondary amine and a diketone, with carbon allotropes in which the carbon is sp.sup.2 hybridized, such as graphene, graphite, fullerene, carbon nanotubes and the like, and an inorganic oxide-hy-droxide. A process for preparing said adducts is also described.

Provided herein are enantioselective organocatalytic methods for preparing chiral tetraaryl methanes.

Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 μM or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.

The present invention is directed to novel compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, and their use.

##STR00001##

The present invention is directed to novel compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, and their use.

##STR00001##

The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.

The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.

The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.